SciSparc Ltd. (SPRC)
| Market Cap | 2.84M -6.0% |
| Revenue (ttm) | 856,000 -34.5% |
| Net Income | -12.18M |
| EPS | 98.07 -51.9% |
| Shares Out | 565.50K |
| PE Ratio | 0.06 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 93,387 |
| Open | 5.39 |
| Previous Close | 5.43 |
| Day's Range | 5.02 - 5.45 |
| 52-Week Range | 2.98 - 80.10 |
| Beta | 2.40 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 24, 2026 |
About SPRC
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer’s disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110, palmitoylethanolamide oral table... [Read more]
Financial Performance
In 2025, SciSparc's revenue was $856,000, a decrease of -34.46% compared to the previous year's $1.31 million. Losses were -$12.18 million, 93.8% more than in 2024.
Financial StatementsNews
Neurothera Labs Announces Continuance into Ontario
April 30, 2026 – TheNewswire - Vancouver, British Columbia, Canada- Neurothera Labs Inc. (TSXV: NTLX) (“ Neurothera ” or the “ Company ”), a clinical-stage biotech company and a majority-owned subsidi...
Neurothera Labs Engages bullVestor for Investor Relations Activities
April 23, 2026 – TheNewswire - Vancouver, British Columbia, Canada - Neurothera Labs Inc. (TSXV: NTLX) ( “ Neurothera ” or the “ Company ”), a clinical-stage biotech company and a majority-owned subsi...
SciSparc discloses patent application for depression yherapy
The company states: “SciSparc (SPRC)has reported that pursuant to NeuroThera’s ongoing collaboration with Clearmind Medicine Inc., a patent application has been filed by Clearmind with the Intellectua...
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pha...
SciSparc’s Neurothera Labs announces publication of international patent
SciSparc (SPRC) announced that NeuroThera Labs, in which SciSparc holds a controlling interest of approximately 75%, has advanced its collaboration with Clearmind Medicine (CMND) with the publication ...
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
TEL AVIV, Israel, March 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pha...
SciSparc says Neurothera Labs agrees to acquire majority stake in CliniQuantum
NeuroThera Labs, in which SciSparc (SPRC)holds a controlling interest of approximately 75%, has entered into a definitive share purchase agreement between NeuroThera, CliniQuantum and the Selling Shar...
SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails
TEL AVIV, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pha...
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
Innovative non-hallucinogenic treatment combines MEAI with Palmitoylethanolamide to address obesity and metabolic dysfunction-associated steatotic liver disease, tapping into a rapidly growing market ...
Neurothera Labs Inc. Announces Definitive Agreement To Acquire Majority Stake In Cliniquantum Ltd.
Vancouver, British Columbia – March 10, 2026 – TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of ...
Scisparc Ltd trading halted, news pending
19:50 EST Scisparc (SPRC)Ltd trading halted, news pending
SciSparc announces 1-for-9 reverse share split
SciSparc (SPRC)announced that it intends to effect a one-for-nine reverse share split of the Company’s issued and outstanding ordinary shares, no par value per share, effective at the market open…
SciSparc announces 1-for-9 reverse share split
SciSparc (SPRC)announced that it intends to effect a one-for-nine reverse share split of the Company’s issued and outstanding ordinary shares, no par value per share, effective at the market open…
SciSparc announces 1-for-9 reverse share split
SciSparc (SPRC)announced that it intends to effect a one-for-nine reverse share split of the Company’s issued and outstanding ordinary shares, no par value per share, effective at the market open…
SciSparc Announces 1-for-9 Reverse Share Split
Following the reverse share split, the Company will have approximately 565,000 outstanding shares, out of which approximately 561,533 will be publicly held Tel Aviv, Israel, March 02, 2026 (GLOBE NEWS...
SciSparc files to sell 23.04M ordinary shares for holders
17:29 EST SciSparc (SPRC)files to sell 23.04M ordinary shares for holders
SciSparc files $50M mixed securities shelf
16:38 EST SciSparc (SPRC)files $50M mixed securities shelf
SciSparc says Neurothera Labs granted U.S. patent for cannabinoid tech
SciSparc (SPRC)announced that NeuroThera Labs, in which SciSparc holds a controlling interest of approximately 75%, announced that the United States Patent and Trademark Office has granted a U.S. pate...
SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA
NeuroThera's Proprietary Cannabinoid-Enhanced Platform Targets Antibiotic Resistance Using Approved Antimicrobials TEL AVIV, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Co...
Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA
Proprietary Cannabinoid-Enhanced Platform Targets Antibiotic Resistance Using Approved Antimicrobials February 2, 2026 – TheNewswire - Vancouver, British Columbia, Canada- Neurothera Labs Inc. (TSXV: ...
SciSparc completes acquisition of IP portfolio of patents, trademarks
SciSparc (SPRC)announced the closing of the acquisition of an IP portfolio of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the ...
SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization
SciSparc intends to target the global multi- billion dollar GERD device market TEL AVIV, Israel, Jan. 26, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company eng...
SciSparc to acquire a treasury of patents for the endoscope market
SciSparc (SPRC)signed a definitive agreement to acquire a treasury of patents, trademarks and intellectual property rights for innovative endoscopic systems and medical cameras, including the MUSE sys...
SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity
SciSparc intends to commence commercialization of these patented technologies immediately following the transaction closing
SciSparc receives noncompliance notification from Nasdaq
SciSparc (SPRC)announced that it has received a written notification from Nasdaq notifying the company that it is no longer in compliance with the minimum stockholders’ equity requirement for continue...